natgillin/translations-raw huggingface dataset:
There are no available data with YESCARTA use in pregnant women. 
Podatkov o uporabi zdravila YESCARTA pri nosečnicah ni.
Prolonged (still present at Day 30 or with an onset at Day 30 or beyond) Grade 3 or higher neutropenia, thrombocytopenia, and anaemia occurred in 26%, 24%, and 10% of patients, respectively. 
Dolgotrajna (ki je še vedno vztrajala na 30. dan ali je nastopila na 30. dan ali po tem) nevtropenija, trombocitopenija in anemija 3. ali višje stopnje se je pojavila pri 26 %, 24 % oz. 10 % bolnikov.
YESCARTA should not be washed, spun down, and/or re-suspended in new media prior to infusion. 
Pred infundiranjem zdravila YESCARTA ni dovoljeno izpirati, centrifugirati in/ali ponovno suspendirati v novem mediju.
Taking into account the PRAC Assessment Report on the PSUR(s) for axicabtagene ciloleucel, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za aksicabtagen ciloleucel je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
Pregnancy after YESCARTA therapy should be discussed with the treating physician. 
O nosečnosti po zdravljenju z zdravilom YESCARTA se je treba posvetovati z zdravnikom, ki vodi zdravljenje.
Thawed product should not be refrozen. 
Odtajanega zdravila ni dovoljeno ponovno zamrzniti.
YESCARTA was administered as a single infusion at a target dose of 2 x 106 anti-CD19 CAR T cells/kg after lymphodepleting chemotherapy regimen of 500 mg/m2 intravenous cyclophosphamide and 30 mg/m2 intravenous fludarabine on the 5th, 4th, and 3rd day before YESCARTA. 
Zdravilo YESCARTA so dali v obliki enkratne infuzije s ciljnim odmerkom 2 x 106 anti-CD19 CAR T-celic/kg po kemoterapiji za uničenje limfocitov po režimu intravenskega ciklofosfamida 500 mg/m2 in intravenskega fludarabina 30 mg/m2 na 5., 4. in 3. dan pred infundiranjem zdravila YESCARTA.
The PRAC considers that the product information of axicabtagene ciloleucel should be amended to reflect the risk of spinal cord oedema, myelitis and quadriplegia associated with axicabtagene ciloleucel therapy. 
Odbor PRAC meni, da je treba informacije o zdravilu za aksicabtagen ciloleucel spremeniti tako, da bodo odražale tveganja za edem hrbtenjače, mielitis in kvadriplegijo, ki so povezani z zdravljenjem z aksicabtagen ciloleucelom.
- have had hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection. 
- če ste imeli okužbo s hepatitisom B, hepatitisom C ali virusom humane imunske pomanjkljivosti (HIV).
This medicine contains genetically modified human blood cells. 
To zdravilo vsebuje gensko spremenjene človeške krvne celice.
YESCARTA is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. 
Zdravilo YESCARTA je indicirano za zdravljenje odraslih bolnikov z difuznim velikoceličnim B-limfomom (DLBCL, diffuse large B-cell lymphoma) in primarnim mediastinalnim velikoceličnim B-limfomom (PMBCL, primary mediastinal large B-cell lymphoma), ki se je ponovil po dveh ali več vrstah sistemskega zdravljenja ali se ni odzival nanje.
The median peak level of anti-CD19 CAR T cells in the blood (Cmax) was 38.3 cells/µL (range: 0.8 to 1513.7 cells/μL), which decreased to a median of 2.1 cells/µL by 1 month (range: 0 to 167.4 cells/μL) and to a median of 0.4 cells/µL by 3 months (range: 0 to 28.4 cells/μL) after YESCARTA infusion. 
Mediana največjih ravni anti-CD19 CAR T-celic v krvi (Cmax) po infundiranju zdravila YESCARTA je bila 38,3 celic/µl (razpon: od 0,8 do 1513,7 celice/μl), ki se je do 1. meseca zmanjšala na mediano 2,1 celice/µl (razpon: od 0 do 167,4 celice/μl), in do 3. meseca na mediano
Your doctor will take some of your blood using a catheter placed in your vein (a procedure call leukapheresis). 
Zdravnik vam bo odvzel nekaj krvi s katetrom, nameščenim v vašo žilo
If visible cell clumps remain, continue to gently mix the contents of the bag. 
Če so v vsebini vreče še vedno vidne celične grudice, nadaljujte z nežnim mešanjem.
N/A = not available/not applicable (a) Lee et al 2014. 
(a) Lee et al 2014.
Before infusion, the patient's identity must match the patient identifiers on the YESCARTA infusion bag and cassette. 
Pred infundiranjem je treba potrditi ujemanje bolnikove identitete z identifikacijskimi informacijami o bolniku na infuzijski vreči in kaseti zdravila YESCARTA.
There are no data regarding the signs of overdose with YESCARTA. 
Podatkov o znakih prevelikega odmerjanja zdravila YESCARTA ni.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CONTAINER (CASSETTE) 
PODATKI NA ZUNANJI OVOJNINI ZUNANJI VSEBNIK (KASETA)
In the primary analysis, based on the mITT population (minimum follow up of 6 months) the ORR was 72% and the complete response (CR) rate was 51%, as determined by an independent review committee. 
V primarni analizi, ki je temeljila na populaciji mITT (najkrajše spremljanje 6 mesecev), je bila po ugotovitvah neodvisne ocenjevalne komisije stopnja ORR 72 % in stopnja celovitega odziva (CR, complete response) 51 %.
Ensure that a minimum of 4 doses of tocilizumab, an interleukin-6 (IL-6) receptor inhibitor, are available for each patient prior to infusion of YESCARTA. 
Pred infundiranjem zdravila YESCARTA se prepričajte, da so za vsakega bolnika na voljo vsaj 4 odmerki tocilizumaba, zaviralca receptorja interlevkina-6 (IL-6).
STOP confirm patient ID prior to infusion. 
STOP - pred infundiranjem potrdite identiteto bolnika.
ITT was defined as all patients who underwent leukapheresis; mITT was defined as all patients who received YESCARTA. 
Populacija, ki so jo nameravali zdraviti (ITT, intention-to-treat), je opredeljena kot vsi bolniki, ki so jim opravili levkaferezo; modificirana populacija, ki so jo nameravali zdraviti (mITT, modified intent-to-treat), je bila opredeljena kot vsi bolniki, ki so prejeli zdravilo YESCARTA.
Allergic reactions may occur with the infusion of YESCARTA. 
Pri infundiranju zdravila YESCARTA se lahko pojavijo alergijske reakcije.
The most common Grade 3 or higher adverse reactions included encephalopathy (31%), unspecified pathogen infections (19%), CRS (11%), bacterial infection (9%), aphasia (7%), viral infection (6%), delirium (6%), hypotension (6%), and hypertension (6%). 
Najpogostejši neželeni učinki 3. ali višje stopnje so vključevali encefalopatijo (31 %), okužbe z neugotovljenimi povzročitelji (19 %), CRS (11 %), bakterijsko okužbo (9 %), afazijo (7 %), virusno okužbo (6 %), delirij (6 %), hipotenzijo (6 %) in hipertenzijo (6 %).
Grade 3 or higher neutropenia (including febrile neutropenia), anaemia, and thrombocytopenia occurred in 80%, 45%, and 40% of patients, respectively. 
Nevtropenija (vključno s febrilno nevtropenijo), anemija in trombocitopenija 3. ali višje stopnje so se pojavile pri 80 %, 45 % oz. 40 % bolnikov.
Hypotension Hypertension 
Zelo pogosti hipotenzija hipertenzija
What you need to know before you are given YESCARTA 
Kaj morate vedeti, preden boste dobili zdravilo YESCARTA Kako se daje zdravilo YESCARTA
Provide intensive-care supportive therapy for severe or lifethreatening neurologic toxicities. 
Pri resnih ali življenje ogrožajočih nevroloških toksičnostih je treba uvesti podporno zdravljenje z intenzivno nego.
The most common signs or symptoms associated with CRS included pyrexia (83%), hypotension (44%), tachycardia (24%), hypoxia (23%), and chills (20%). 
Najpogostejši znaki ali simptomi, povezani s CRS, so vključevali pireksijo (83 %), hipotenzijo (44 %), tahikardijo (24 %), hipoksijo (23 %) in mrzlico (20 %).
Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and YESCARTA infusion. 
Pri bolnikih lahko citopenija vztraja več tednov po kemoterapiji za uničenje limfocitov ter infundiranju zdravila YESCARTA.
To prepare YESCARTA, patient's own T cells are harvested and genetically modified ex vivo by retroviral transduction to express a chimeric antigen receptor (CAR) comprising a murine anti-CD19 single chain variable fragment linked to CD28 co-stimulatory domain and CD3-zeta signalling domain. 
Za pripravo zdravila YESCARTA se bolniku odvzamejo T-celice, ki se gensko spremenijo ex vivo z retrovirusno transdukcijo, da izražajo himerni antigenski receptor (CAR, chimeric antigen receptor), ki ga sestavlja murini anti-CD19 enoverižni fragment variabilnih regij, povezan s kostimulativno domeno CD28 in signalno domeno CD3-zeta.
YESCARTA contains sodium 
Zdravilo YESCARTA vsebuje natrij
Gilead Sciences Ltd Tel: + 44 (0) 8000 113700 
Velika Britanija Gilead Sciences Ltd Tel: + 44 (0) 8000 113700
No dose adjustment is required in patients ≥ 65 years of age. 
Pri bolnikih, starih ≥ 65 let, odmerka ni treba prilagajati.
YESCARTA is a type of medicine called a “genetically modified cell therapy”. 
Kaj je zdravilo YESCARTA in za kaj ga uporabljamo Zdravilo YESCARTA je vrsta zdravila, ki se imenuje »zdravljenje z gensko spremenjenimi celicami«.
Secondary malignancies 
Sekundarna maligna obolenja
Contraindications of the lymphodepleting chemotherapy must be considered. 
Upoštevati je treba kontraindikacije za kemoterapijo za uničenje limfocitov.
Take your temperature twice a day for 3-4 weeks after treatment with YESCARTA. 
Po zdravljenju z zdravilom YESCARTA si 3 do 4 tedne dvakrat na dan merite telesno temperaturo.
To minimise the risks associated with the treatment of YESCARTA, the MAH must ensure that hospitals and their associated centres that dispense YESCARTA are specially qualified in accordance with the agreed control distribution program. 
Za zmanjšanje tveganj, povezanih z zdravljenjem z zdravilom YESCARTA, mora imetnik dovoljenja za promet z zdravilom zagotoviti, da so bolnišnice in njihovi povezani centri, ki izdajajo zdravilo
YESCARTA (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy. 
Zdravilo YESCARTA (aksicabtagen ciloleucel) je proti CD19 usmerjena, gensko spremenjena avtologna T-celična imunoterapija.
• Check that the patient information on the cassette label matches that on the bag label. 
• Preverite, ali se informacije o bolniku na nalepki na kaseti ujemajo s tistimi na nalepki na vreči.
Some people may feel tired, dizzy or have some shaking after being given YESCARTA. 
Vpliv na sposobnost upravljanja vozil in strojev Nekateri ljudje so lahko utrujeni, omotični ali se po dajanju zdravila YESCARTA tresejo.
The median time to onset was 5 days (range: 1 to 17 days). 
Mediani čas do pojava je bil 5 dni (razpon od 1 do 17 dni).
Do not refreeze. 
Ne obsevajte.
Administer methylprednisolone 1000 mg intravenously per day for 3 days; if improves, then manage as above. 
3 dni naj se daje metilprednizolon 1.000 mg intravensko na dan; pri izboljšanju obravnava kot zgoraj.
YESCARTA 0.4 - 2 x 108 cells dispersion for infusion 
YESCARTA 0,4-2 × 108 celic disperzija za infundiranje
The most common signs or symptoms associated with neurologic adverse reactions included encephalopathy (58%), headache (40%), tremor (31%), dizziness (21%), aphasia (18%), and delirium (17%). 
Najpogostejši znaki ali simptomi, povezani z nevrološkimi neželenimi učinki, so vključevali encefalopatijo (58 %), glavobol (40 %), tremor (31 %), omotico (21 %), afazijo (18 %) in delirij (17 %).
Oxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity (b). 
FiO2 ali hipotenzivni odziv na tekočine ali majhni odmerki enega od vazopresorjev ali toksičnost organov 2. stopnje (b).
Any unused medicine or waste material must be disposed of in accordance with local biosafety guidelines. 
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi smernicami za zagotavljanje biološke varnosti.
YESCARTA comprises human autologous T cells. 
Zdravilo YESCARTA vsebuje človeške avtologne T-celice.
The MAH must ensure on-site, immediate access to 4 doses of tocilizumab for each patient as CRS management medication prior to treating patients. 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je pred zdravljenjem bolnika na kraju samem zagotovljen takojšnji dostop do najmanj 4 odmerkov tocilizumaba za vsakega bolnika kot zdravilo za obravnavo CRS.
Grade 3 or higher neutropenia, thrombocytopenia, and anaemia present after Day 93 occurred in 11%, 7%, and 3% of patients, respectively. 
Nevtropenija, trombocitopenija in anemija 3. ali višje stopnje, ki je vztrajala tudi po 93. dnevu, se je pojavila pri 11 %, 7 % oz. 3 % bolnikov.
Duration of Responsea, CR, median (range) in months 
Trajanje odzivaa, CR, mediana
Monitor patients life-long for secondary malignancies. 
Potrebno je doživljenjsko spremljanje bolnikov glede pojava sekundarnih malignih obolenj.
Severe CRS, including life-threatening and fatal reactions, was very commonly observed with YESCARTA with a time to onset of 1 to 12 days (see section 4.8). 
Hud CRS, vključno s smrtno nevarnimi in smrtnimi reakcijami, so pri zdravilu YESCARTA opazili zelo pogosto, s časom do pojava od 1 do
Preparation of YESCARTA 
Priprava zdravila YESCARTA
• Central venous access is recommended for the administration of YESCARTA. 
• Pri dajanju zdravila YESCARTA se priporoča centralni venski dostop.
YESCARTA is to be administered via intravenous infusion. 
Zdravilo YESCARTA se daje z intravensko infuzijo.
YESCARTA is made specially for you as a single administration of your own modified white blood cells. 
Zdravilo YESCARTA je izdelano posebej za vas za enkratno dajanje vaših lastnih belih krvnih celic,
There is limited experience with YESCARTA in patients exposed to prior CD19-directed therapy. 
Izkušnje z zdravljenjem z zdravilom YESCARTA pri bolnikih, izpostavljenih predhodni terapiji, usmerjeni proti CD19, so omejene.
Neurologic adverse reaction grading and management guidance 
Preglednica 2: Stopnje nevroloških neželenih učinkov in navodila za obravnavo
It is unknown whether YESCARTA is excreted in human milk or transferred to the breast-feeding child. Breast-feeding women should be advised of the potential risk to the breast-fed child. 
Ni znano, ali se zdravilo YESCARTA izloča v materino mleko ali prenaša na dojenega otroka.
YESCARTA contains genetically modified human blood cells. 
Zdravilo YESCARTA vsebuje gensko spremenjene človeške krvne celice.
Each patient specific single infusion bag of YESCARTA contains a dispersion of anti-CD19 CAR T cells in approximately 68 mL for a target dose of 2 x 106 anti-CD19 CAR-positive viable T cells/kg body weight (range: 1 x 106 - 2 x 106 cells/kg), with a maximum of 2 x 108 anti-CD19 CAR T cells. 
Ena vreča za enkratno infundiranje zdravila YESCARTA, specifična za bolnika, vsebuje disperzijo anti-CD19 CAR T-celic v približno 68 ml za ciljni odmerek 2 x 106 anti-CD19 CAR-pozitivnih viabilnih T-celic/kg telesne mase (razpon: 1 x 106 - 2 x 106 celic/kg), z največ 2 x 108 anti-CD19 CAR T-celic.
Motor dysfunction Pain in extremity Back pain Arthralgia Muscle pain 
Bolezni mišično-skeletnega sistema in vezivnega tkiva Zelo pogosti motorična disfunkcija bolečine v okončinah bolečine v hrbtu artralgija bolečina v mišicah
• Prime the tubing with 0.9% sodium chloride solution (0.154 mmol sodium per mL) prior to infusion. 
• Cevje pred infundiranjem napolnite z 0,9 % raztopino natrijevega klorida (0,154 mmol natrija na ml).
Gently mix the contents of the bag while thawing. 
Med odtajanjem nežno mešajte vsebino vreče.
Renal insufficiency 
Pogosti ledvična insuficienca
Manage per Grade 3 if no improvement within 24 hours after starting tocilizumab. 
Če v 24 urah po uvedbi tocilizumaba ni izboljšanja, ravnajte v skladu z navodili za
After you have been given YESCARTA Tell your doctor or nurse immediately if you have any of the following: 
Zdravniku ali medicinski sestri takoj povejte, če opazite kaj od naslednjega:
• An antihistamine such as diphenhydramine. 
• paracetamol • antihistaminik, na primer difenhidramin.
Neurologic adverse reactions 
Nevrološki neželeni učinki
The stability of YESCARTA upon completion of thawing is up to 3 hours at room temperature (20 ˚C to 25 °C). 
Zdravilo YESCARTA je po končanem odtajanju stabilno do 3 ure pri sobni temperaturi (20 °C do 25 °C).
- have kidney problems. 
- če imate težave z ledvicami.
Screening for HBV, HCV, and HIV should be performed in accordance with clinical guidelines before collection of cells for manufacturing of YESCARTA. 
Pred odvzemom celic za izdelavo zdravila YESCARTA je treba izvesti presejalne teste za HBV, HCV in HIV v skladu s kliničnimi smernicami.
The median time to response was 1.0 months (range: 0.8 to 12.2 months). 
1,0 meseca (razpon: 0,8 do 12,2 meseca).
Administer dexamethasone 10 mg intravenously every 6 hours. 
Vsakih 6 ur naj se daje deksametazon 10 mg intravensko.
Counsel patients to remain within proximity of a qualified clinical facility for at least 4 weeks following infusion and to seek immediate medical attention should signs or symptoms of neurologic toxicity occur. 
Bolnikom je treba svetovati, da naj se vsaj 4 tedne po infundiranju zadržujejo blizu usposobljene klinične ustanove in da naj takoj poiščejo zdravniško pomoč, če se pojavijo znaki ali simptomi nevrološke toksičnosti.
Unspecified pathogen infections Viral infections 
Zelo pogosti okužbe z neugotovljenimi povzročitelji virusne okužbe bakterijske okužbe
Cytokine Release Syndrome Hypogammaglobulinaemia 
Zelo pogosti sindrom sproščanja citokinov hipogamaglobulinemija
Store frozen in vapour phase of liquid nitrogen ≤ -150 °C until thawed for use. 
Shranjujte zamrznjeno v parni fazi tekočega dušika pri temperaturi ≤ -150 °C do odtajanja pred uporabo.
YESCARTA is stable at room temperature for up to 3 hours after thaw. 
Zdravilo YESCARTA je na sobni temperaturi po odtajanju stabilno do 3 ure.
Before you are given YESCARTA you should tell your doctor if you: 
Preden boste dobili zdravilo YESCARTA, bo zdravnik:
- have problems with your nervous system (such as fits, stroke, or memory loss). 
Preden dobite zdravilo YESCARTA, morate zdravniku povedati: - če imate težave z živčevjem (kot so epileptični napadi, možganska kap ali izguba spomina).
See the prescribing information for lymphodepleting chemotherapy for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy. 
Za informacije glede potrebne učinkovite kontracepcije pri bolnicah, ki prejmejo kemoterapijo za uničenje limfocitov, glejte navodila za predpisovanje kemoterapije za uničenje limfocitov.
Counsel patients to remain within proximity of a qualified clinical facility for at least 4 weeks following infusion and to seek immediate medical attention should signs or symptoms of CRS occur. 
Bolnikom je treba svetovati, da naj se vsaj 4 tedne po infundiranju zadržujejo blizu usposobljene klinične ustanove in da takoj poiščejo zdravniško pomoč, če opazijo znake ali simptome CRS.
Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (CAR) with a target dose of 2 x 106 anti-CD19 CAR-positive viable T cells/kg. 
Avtologne T-celice, transducirane z retrovirusnim vektorjem, ki kodira anti-CD19 himerni antigenski receptor (CAR, chimeric antigen receptor) CD28/CD3-zeta s ciljnim odmerkom 2 x 106 anti-CD19
Spinal cord oedema was reported, in the context of neurologic toxicity in the post-marketing setting. 
V obdobju trženja so v okviru nevrološke toksičnosti poročali o edemu hrbtenjače.
Hypocalcaemia Hypoalbuminaemia 
Pogosti hipokalciemija hipoalbuminemija
- Your doctor will give you a Patient Alert Card. Read it carefully and follow the instructions on it. - Always show the Patient Alert Card to the doctor or nurse when you see them or if you go to hospital. 
- Če greste k zdravniku ali medicinski sestri ali pa v bolnišnico, vedno pokažite opozorilno kartico za bolnika.
- Heart failure. 
Srčne bolezni
• Paracetamol 500-1,000 mg given orally and diphenhydramine 12.5 to 25 mg intravenous or oral 
Premedikacija • Približno 1 uro pred infundiranjem zdravila YESCARTA je priporočljivo dati 500-1.000 mg paracetamola peroralno in 12,5 mg do 25 mg difenhidramina intravensko ali peroralno (ali ekvivalentno zdravilo).
Monitor patients daily for signs and symptoms of CRS for at least 10 days following infusion at the qualified clinical facility. 
Bolnike je treba vsaj 10 dni po infundiranju vsak dan spremljati glede znakov in simptomov CRS v usposobljeni klinični ustanovi.
YESCARTA 0.4 - 2 x 108 cells dispersion for infusion axicabtagene ciloleucel (CAR+ viable T cells) 
YESCARTA 0,4-2 x 108 celic disperzija za infundiranje aksicabtagen ciloleucel (CAR+ viabilne T-celice)
Thirty-two percent (32%) of patients experienced Grade 3 or higher (severe or life-threatening) adverse reactions. 
Nevrološki neželeni učinki so se pojavili pri 67 % bolnikov, pri čemer je 32 % bolnikov imelo neželene učinke 3. ali višje stopnje (hude ali smrtno nevarne).
Evaluation for haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) should be considered in patients with severe or unresponsive CRS. 
Pri bolnikih s hudim ali neodzivnim CRS je treba pomisliti na sindrom hemofagocitne limfohistiocitoze/aktivacije makrofagov (HLH/MAS, haemophagocytic lymphohistiocytosis/macrophage activation syndrome).
Prophylactic anti-microbials should be administered according to standard institutional guidelines. 
V skladu s standardnimi smernicami ustanove je treba profilaktično dajati protimikrobna snovi učinkovine.
It is not known if YESCARTA has the potential to be transferred to the foetus. 
Ni znano, ali se lahko zdravilo YESCARTA prenaša na plod.
Grade 1 
1. stopnja
Eleven percent (11%) of patients experienced Grade 3 or higher (severe, life-threatening, and fatal) CRS. 
CRS se je pojavil pri 93 % bolnikov, pri čemer je bil CRS pri 11 % bolnikov 3. ali višje stopnje (huda oblika, smrtno nevaren in smrten).
NE (0.4, 29.5) 
NO (0,4, 17,3) NO (0,4, 29,5) NO (0,4, 17,3) NO (0,4, 29,5)
HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. 
Pri bolnikih, zdravljenih z zdravili, usmerjenimi proti B-celicam, se lahko pojavi reaktivacija HBV, ki v nekaterih primerih povzroči fulminantni hepatitis, odpoved jeter in smrt.
Consider alternate immunosuppressants if no improvement or if condition worsens. 
Če ni izboljšanja ali se stanje poslabša, razmislite o drugem imunosupresivu.
Fatal and serious cases of cerebral oedema have been reported in patients treated with YESCARTA. 
Pri bolnikih, zdravljenih z zdravilom YESCARTA, so poročali o smrtnih in resnih primerih možganskega edema.
There is no experience of use of YESCARTA in patients with primary CNS lymphoma. 
Primarni limfom osrednjega živčnega sistema (OŽS) Izkušenj z uporabo zdravila YESCARTA pri bolnikih s primarnim limfomom OŽS ni.
Per Grade 2 
Kot 2. stopnja
Respiratory, thoracic and mediastinal disorders Very common 
Bolezni dihal, prsnega koša in mediastinalnega prostora Zelo pogosti kašelj dispneja hipoksija plevralni izliv
Thrombosis Capillary leak syndrome 
Pogosti tromboza sindrom kapilarne krvavitve
• Verify that the patient's identity (ID) matches the patient identifiers on the YESCARTA cassette. 
• Potrdite, da se identiteta (ID) bolnika ujema z identifikacijskimi oznakami bolnika na kaseti zdravila YESCARTA.
Store frozen in vapour phase of liquid nitrogen ≤ -150˚C. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte zamrznjeno v parni fazi tekočega dušika ≤ -150 °C.
Adverse reactions Dyscalculia Myoclonus 
Pogosti ataksija nevropatija epileptični napadi diskalkulija mioklonus
After you are given YESCARTA 
Po tem, ko prejmete zdravilo YESCARTA
YESCARTA must not be irradiated. 
Zdravila YESCARTA ni dovoljeno obsevati.
After the first 10 days following the infusion, the patient should be monitored at the physician's discretion. 
Po prvih 10 dneh po infundiranju je treba bolnika spremljati po presoji zdravnika.